Looking Back on ‘Yes, We Can Cannabizz’ – An Evening Shaping the Future of Medical Cannabis

On Thursday, November 14, 2024, we hosted our exclusive event “Yes, we can Cannabizz” in Berlin—a gathering that brought together top leaders from the cannabis industry, medical professionals, patients, and pharmacists. With nearly 100 guests, the event provided a unique platform to explore the opportunities and challenges facing both the German and international cannabis markets.

For those who couldn’t attend, here’s a recap of the day’s highlights. Against the backdrop of political uncertainty and an impending government transition, the event underscored one clear message: collaboration across all stakeholders is essential to safeguard the progress made over the past months and actively shape the future of medicinal cannabis in Germany.

Event Highlights

Yes, we can Cannabizz: Berner, CEO of Cookies, and Transatlantic Perspectives

The event kicked off with a compelling business panel featuring Berner, founder and CEO of Cookies, alongside Jakob and Benedikt Sons from Cansativa Group. Moderated by Bijan Hezarkhani, the discussion offered attendees an exclusive look into the experiences of a global cannabis market leader. Since its founding in 2010, Cookies has operated across diverse international markets, navigating varying regulatory landscapes in both the medicinal and recreational sectors.

Berner emphasized the importance of quality, innovative genetics, and a patient- and consumer-focused approach as cornerstones of long-term success. His insights resonated deeply with Germany’s young and evolving cannabis industry, offering a roadmap for sustainable growth and stability. As the world’s most successful cannabis brand, Cookies set a benchmark for innovation and excellence.

Having Berner in Berlin to share his journey was a rare privilege and an inspiration for all in attendance. We thank him for joining us and providing invaluable insights that will guide the industry forward.

Yes, we can help: 200 Days of the New Cannabis Law – What’s Changed?

The second panel explored the medical landscape under the new legislation. Moderated by Bertan Türemis (Fette Pharma), the discussion brought together leading experts, including Prof. Dr. med. Kirsten R. Müller-Vahl (Medizinische Hochschule Hannover), Melanie Dolfen (Bezirksapotheke), Gero Kohlhaas (Selbsthilfenetzwerk Cannabismedizin), and Finn Age Hänsel (Sanity Group).

Since the introduction of the Medicinal Cannabis Law (MedCanG) in April 2024, several critical improvements have been made. Removing medicinal cannabis from the Controlled Substances Act has simplified prescribing processes, strengthened doctors’ autonomy, and significantly reduced administrative burdens. However, the panelists agreed that there’s still much work to be done.

The absence of Pillar II, which would establish commercial supply chains, continues to hinder the clear separation between medical and recreational cannabis use. Prof. Müller-Vahl highlighted this gap:

“Without Pillar II, the supply gap persists. Commercial structures are essential to combat the black market effectively and protect both patients and consumers.”

Adding to the industry’s concerns is the political uncertainty surrounding the upcoming government transition. The Union’s pledge to roll back parts of the cannabis legalization framework has caused widespread unease. Finn Age Hänsel voiced his worries:

“A coalition with the Union would be the worst outcome for us. They’ve already signaled their intent to stop legalization, and the SPD likely won’t push back enough.”

Yes, we can all benefit: Exploring Cannabis Quality Under the Microscope

The day concluded with an engaging workshop led by Yordanka Caglar from Tiergarten Apotheke Konstanz. Attendees had the opportunity to analyze various cultivars of medicinal cannabis under the microscope, examining quality indicators such as color, aroma, and terpene profiles. The workshop reinforced the importance of rigorous quality assurance in maintaining trust and meeting patient needs. High standards are essential for building confidence in medicinal cannabis as a therapeutic option.

The “Yes, we can Cannabizz” event demonstrated the power of collaboration and dialogue within this dynamic and growing industry. We thank all speakers and attendees for making this day a memorable one. Together, we are poised to navigate the challenges ahead and continue building a stronger, more resilient cannabis sector.

Explore more moments from ‘Yes, We Can Cannabizz’ in our picture gallery. View Gallery

Anything else?

Do you have specific questions or suggestions for the Cannabis Briefing? Then send us an email to briefing@cansativa.de. If you are interested in revolutionising the cannabis industry with us, then stay tuned and follow our briefings!

We wish you a good read!

With legalising greetings,